PDCD1 and non-small cell lung carcinoma: More recently, immune checkpoint inhibitor agents targeting programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have been established as a new treatment for advanced NSCLC patients.